Showing results (491-500 of 1,877) with videos related to

Sort By:
Pageof 188
Immunotherapy|April 29, 2015
A Phase I clinical trial with subcutaneous immunotherapy vaccine of Timothy grass pollen extract according to EMA guidelinesJavier Sola, Vanesa Sánchez, Araitz Landeta, et al.
Immunotherapy|April 29, 2015
Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?Fabiola Atzeni, Luigi Gianturco, Rossella Talotta, et al.
Immunotherapy|April 29, 2015
New York esophageal squamous cell carcinoma-1 and cancer immunotherapyAli Esfandiary, Soudeh Ghafouri-Fard
Immunotherapy|August 4, 2016
Cytokine-induced killer cell therapy-associated idiopathic thrombocytopenic purpura: rare but noteworthyXiaomin Fu, Yong Zhang, Quanli Gao, et al.
Immunotherapy|August 4, 2016
PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysisOmar Abdel-Rahman
Immunotherapy|August 4, 2016
Anti-GD2 mAbs and next-generation mAb-based agents for cancer therapyZulmarie Perez Horta, Jacob L Goldberg, Paul M Sondel
Immunotherapy|April 7, 2021
Immunotherapy retreatment: case report, review of the literature and proposal for the definition of different scenariosRoberto Borea, Alessandra Damassi, Sara Elena Rebuzzi, et al.
Immunotherapy|April 7, 2021
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidenceAlessandro Rizzo, Matteo Rosellini, Andrea Marchetti, et al.
Immunotherapy|September 1, 2025
Scalable and cost-effective CAR-T exosome therapies: challenges and future directionsXuan Zhao, Huixian Li, Xinwei Zhao, et al.
Immunotherapy|July 29, 2016
Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerabilityRichard L Wasserman, Isaac Melamed, Lisa Kobrynski, et al.
Pageof 188